Vista Pharmaceuticals Limited has filed its quarterly compliance certificate with BSE Limited, confirming adherence to SEBI regulations for dematerialization processes during the quarter ended 31.03.2026.

Regulatory Compliance Filing

The company submitted its compliance certificate under Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018 on 14.04.2026. The certificate was signed by Dhananjaya Alli, Executive Director (DIN: 00610909), and addressed to BSE Limited at Phiroze Jeejeebhoy Towers, Mumbai.

Registrar Confirmation

Aarthi Consultants Private Limited, serving as the company's Registrar and Transfer Agent, provided the underlying certificate confirming compliance with dematerialization requirements. The registrar, holding SEBI Registration No. INR000000379, certified completion of all required actions for the period from 01.01.2026 to 31.03.2026.

Compliance Actions Completed

The registrar confirmed execution of the following mandatory procedures:

• Mutilation and cancellation of physical security certificates forwarded by depository participants
• Substitution of depository names as registered owners in company records
• Verification that dematerialized securities are listed on appropriate stock exchanges
• Completion of all actions within the stipulated 15-day timeframe

Certificate Details

The compliance certificate confirms that Vista Pharmaceuticals Limited has met all regulatory requirements for dematerialization processes during the specified quarter. The certificate was issued by Jagan Mohan Gobburi, Compliance Officer at Aarthi Consultants Private Limited, dated 03.04.2026.

This filing represents Vista Pharmaceuticals Limited's ongoing commitment to regulatory compliance and transparent reporting to stock exchange authorities and stakeholders.

Vista Pharmaceuticals Limited has reported its unaudited financial results for the quarter and nine months ended December 31, 2025, showing a significant deterioration in financial performance. The pharmaceutical manufacturer posted a net loss of ₹231.94 lakhs for the third quarter of FY26, representing a substantial increase from the ₹132.23 lakhs loss recorded in the corresponding quarter of the previous year.

Financial Performance Overview

The company's quarterly performance reflected challenging operating conditions across key metrics:

Nine-Month Performance Analysis

The nine-month results showed an even more pronounced decline in the company's financial position:

Key Financial Highlights

The company's earnings per share deteriorated significantly, with basic EPS for the quarter at ₹(0.41) compared to ₹(0.07) in the previous year. For the nine-month period, the basic EPS stood at ₹(1.05) against ₹(0.53) in the corresponding period of FY25.

Significant Provisions and Adjustments

During the third quarter, Vista Pharmaceuticals recognized a provision for Expected Credit Loss amounting to ₹205.43 lakhs against long-pending trade receivables. This provision was made in accordance with Ind AS 109 - Financial Instruments requirements, reflecting management's assessment of credit losses expected on receivables outstanding for extended periods.

Outstanding Statutory Liabilities

As of December 31, 2025, the company reported outstanding statutory liabilities totaling ₹95.48 lakhs, comprising:

The company attributed the delay in payments to working capital management challenges and indicated its intention to clear these dues in subsequent periods.

Board Approval and Compliance

The financial results were approved by the Board of Directors at their meeting held on February 13, 2026, following recommendation by the Audit Committee. The meeting commenced at 2:30 PM IST and concluded at 3:10 PM IST. The statutory auditors A.M Reddy & D.R Reddy conducted a limited review of the unaudited financial results as required under Regulation 33 of SEBI (LODR) Regulations, 2015.

The auditors highlighted two emphasis matters in their review report: the Expected Credit Loss provision of ₹205.43 lakhs and the outstanding statutory dues of ₹95.48 lakhs, while confirming that their conclusion was not modified by these matters.